Furthermore, the timing of sample collection in suspected germline TP53 carriers plays a significant role in result interpretation, as somatic TP53 is one of the most common CH lesions [45, 56–58], In the paired blood-tumor analysis from MSK-IMPACT the samples obtained from older patients, or following chemotherapy administration were found to have higher rate of somatic TP53 mutations most likely representing chemotherapy-included CH rather than germline TP53 variants [53, 55]. This evidence concerns the gene TP53 and cyclic hematopoiesis.